Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
9
×
life sciences
national blog main
boston top stories
clinical trials
biotech
national top stories
new york blog main
san francisco blog main
boston
new york top stories
san diego blog main
san francisco top stories
drugs
san diego top stories
alnylam pharmaceuticals
bristol-myers squibb
gene therapy
medical devices
new york
pfizer
rna interference
roche
accelerated approval
acute hepatic porphyria
aldehyde
aldeyra therapeutics
alirocumab
allergan
allergic conjunctivitis
amgen
aminolevulinic acid
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biofourmis
biomarin
biovotion
bluebird bio
What
data
9
×
drug
new
medical
medicine
therapeutics
alnylam
devices
long
market
medicines
pharmaceuticals
rna
step
ago
aldeyra
analytics
annual
approved
attacks
awards
based
biofourmis
biotechs
breast
cancer
cancer's
cholesterol
cleared
clinical
close
closer
conference
considering
cyber
digital
disclosed
disease
diseases
dna
Language
unset
Current search:
" boston blog main "
×
data
×
@xconomy.com
4 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Roswell, Organovo & More: Xconomy Awards Innovation at the Intersection Finalists
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug